A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HNC / head and neck carcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 43
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HNC  (>> Co-occurring Abbreviation)
Long Form:   head and neck carcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Effects of Salivary Mg on Head and Neck Carcinoma via TRPM7. ---
2019 Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma. CI, HR, NPC
2018 Deep hyperthermia with the HYPERcollar system combined with irradiation for advanced head and neck carcinoma - a feasibility study. RT
2018 Human Papillomavirus-Related Neuroendocrine Carcinomas of the Head and Neck. HPV, LCNEC, SCC
2017 ()-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ---
2017 The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. HPV-positive OPC
2016 Does CYP2E1 RsaI/PstI polymorphism confer head and neck carcinoma susceptibility?: A meta-analysis based on 43 studies. CI, OR
2016 Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. ENT
2016 Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals. CIs, MDM2, ORs
10  2016 Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells. ---
11  2016 Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. LC3-II, NF-kappaB, ROS, Vio
12  2016 [Human papilloma viruses: other risk factor of head and neck carcinoma]. HPVs, RF
13  2015 Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies. ---
14  2014 An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: inferior outcomes for African American males in the LORHAN database. AA, OS, PFS
15  2014 Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. CI, CTCs, EGFR, HR, OS, PFS, R/M
16  2014 Proteomic study of HPV-positive head and neck cancers: preliminary results. eEF1alpha, HPV, PSCA
17  2014 Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. EGFR, OPC, OS, PFS
18  2013 Dosimetric influences of rotational setup errors on head and neck carcinoma intensity-modulated radiation therapy treatments. AP, CBCT, CTV, IMRT, LR, PTV, SI
19  2013 Genetic variation of fifteen folate metabolic pathway associated gene loci and the risk of incident head and neck carcinoma: the Women's Genome Health Study. FMP, RFC1, tSNPs
20  2012 Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis. NAT2, ORs
21  2012 Complementary and alternative medications consumed by patients with head and neck carcinoma: a pilot study in Germany. CAM
22  2012 Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). LORHAN
23  2011 Hyperfractionated radiation therapy and concurrent chemotherapy for advanced head and neck cancer. CR, OS, PFS, PR
24  2010 Anti-cancer effects of celecoxib in head and neck carcinoma. COX2
25  2010 Human papillomavirus in the etiology of head and neck carcinomas. HPV
26  2008 Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. PET, SUV
27  2008 Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. CT, FDG, MRI, SPECT, T/B
28  2008 Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors. GLUT
29  2008 The effect of socioeconomic factors on quality of life after treatment in patients with head and neck cancer. MCS, PCS, QOL
30  2007 Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. AR, EGF, NSCLC, sEGFR, TGF-alpha
31  2007 [Epidermal growth factor receptor (EGF) in head-and-neck cancers]. EGF
32  2006 Coping preferences of head and neck cancer patients - Indian context. EOC, POC
33  2006 Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. cGy, OM, OR, SD
34  2005 Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. ---
35  2002 An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck. QOL
36  2002 Genomic instability at the human CD5 gene promoter. B-CLL, MCL, MS, PCR
37  2001 Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Gy
38  2001 Pretreatment prevalence of hypothyroidism in patients with head and neck carcinoma. ---
39  1998 Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. CI, RTOG, WHO
40  1998 Mechanisms responsible for signaling and functional defects. TCR
41  1997 Pain experienced by patients with terminal head and neck carcinoma. SD, VAS, WHO
42  1997 [Mutation and methylation of CDKN2 gene in human head and neck carcinomas]. ---
43  1995 Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. VNR